Audit Trails
Computer-generated records of every operator action on regulated data — date, time, identity — retained with the record, tamper-protected, and available for FDA inspection.
Part 11 defines the technical and procedural standards electronic systems must meet to be accepted by the FDA as equivalent to paper records and handwritten signatures.
Computer-generated records of every operator action on regulated data — date, time, identity — retained with the record, tamper-protected, and available for FDA inspection.
Unique per individual, cryptographically linked to their record, and displaying the signer's full name, timestamp, and meaning — review, approval, or authorship.
Systems must be validated through IQ, OQ, and PQ phases with documentation updated whenever changes affect the validated state.
Identity verification and role-based controls limit each user to authorized functions, enforce permitted sequencing, and anchor reliable audit trails.
Records must stay accurate and retrievable across multi-decade retention periods. Archive formats and backup procedures are planned from day one.
Part 11 governs electronic systems where a predicate rule requires records. Mapping each rule — GCP, Part 820, CLIA — defines the compliance perimeter and drives validation scope.
From predicate rule mapping to validation documentation — each step produces specific deliverables that determine whether a system will pass FDA inspection.
Pharmaceutical companies, contract research organizations, and medical device manufacturers will not deploy software that has not been designed and validated with Part 11 requirements in mind — doing so would jeopardize their own FDA compliance posture. Click through to see what is at stake.
Book a Part 11 Compliance ConsultationEach requirement maps to specific software design decisions and validation deliverables — architectural commitments made before development begins. Hover a card to see what each demands.
Computer-generated audit trails must capture every action on regulated records — date, time, operator identity, and create/modify/delete events — in tamper-protected storage retained with the record and available for FDA inspection.
Electronic signatures must be unique, non-reusable, and cryptographically linked to the record — displaying full name, date, time, and the meaning of the signature.
Systems must be validated through a structured three-phase protocol — IQ, OQ, PQ — with traceability matrices, a Validation Summary Report, and a change control program before generating regulated records.
System access must be limited to authorized individuals with role-appropriate function restrictions — identity verification, unique user IDs, permitted-sequence enforcement, and session management controls.
Electronic records must remain accurate, complete, and retrievable across multi-decade retention periods — technology-independent archiving, backup and recovery, format stability, and audit-trail co-retention.
Part 11 applies only where a predicate rule requires records — 21 CFR Part 820, GCP, CLIA, GMP, and submission records. Scope definition is the first compliance step.
Validation frameworks, audit logging infrastructure, electronic signature tooling, and regulated cloud environments — selected to match the predicate rule scope and inspection readiness requirements of FDA-regulated software deployments.
We build Part 11 compliance into clinical trial, medical device, and laboratory software — audit trails, electronic signatures, IQ/OQ/PQ validation, and the documentation package FDA inspectors require.
Book a Part 11 Compliance Consultation
100 Fastest Growth Companies
Global Spring Winner
Top App Development Company
AWS Partner Network
Google Cloud Partner
Highly Rated on Trustpilot
Verified Agency
Top App Development Company
ASSOCHAM Member
No. Part 11 applies specifically to electronic records that are required to be maintained or submitted to the FDA under an applicable FDA predicate rule, and to electronic signatures used on those records. Clinical trial data management software, medical device quality management systems, laboratory systems used in FDA-regulated research, and manufacturing execution systems in pharmaceutical facilities are common Part 11 environments. Electronic health record systems used in routine clinical care, patient-facing health apps, and other health technology products that do not support FDA-regulated activities are not subject to Part 11, though they may be subject to other regulatory requirements including HIPAA.
21 CFR Part 11 governs electronic records and electronic signatures. 21 CFR Part 820, commonly called the Quality System Regulation, governs the quality management requirements for medical device manufacturers. Part 820 requires that medical device manufacturers maintain design history files, device master records, quality records, and complaint files, among others. When those records are maintained electronically, Part 11 applies to the electronic systems used to maintain them. Part 820 is currently being harmonized with ISO 13485, the international medical device quality management standard, through FDA's Quality Management System Regulation update. Digital health companies building software for medical device manufacturers need to understand both regulations and how they interact.
Computer system validation is the documented process of establishing and verifying that a computer system consistently produces a result meeting its predetermined specifications and quality attributes. Part 11 requires that systems used to create, modify, maintain, or transmit regulated records be validated to ensure accuracy, reliability, consistent intended performance, and the ability to discern invalid or altered records. Validation follows a structured three-phase methodology: Installation Qualification, Operational Qualification, and Performance Qualification. Each phase produces documented test results that constitute evidence of the system's validated state. Validation documentation must be maintained and updated when the system changes in ways that could affect its validated state.
FDA inspections of pharmaceutical manufacturers and clinical trial sponsors routinely include examination of the computer systems used to generate and maintain regulated records. When Part 11 deficiencies are found — inadequate audit trails, improperly controlled electronic signatures, unvalidated systems, or insufficient access controls — the FDA can issue Form 483 observations, which must be formally responded to. Serious or repeated deficiencies can result in warning letters that are publicly posted, import alerts that block product entry into the US market, or clinical hold actions that halt ongoing clinical trials. For regulated customers, these consequences create strong demand for software that has been designed and validated with Part 11 requirements from the start.